Evidence map›Paper›PMID 38597472›Full record

ArticleRevista peruana de medicina experimental y salud publica

Characteristics and factors associated with mortality in tracheostomized patients with COVID-19: a retrospective cohort study in a hospital in Tacna, Peru.

Rodrigo Jesús Flores Palacios, Miguel Hueda Zavaleta, Andrés Guillermo Gutiérrez Avila, Juan Carlos Gómez de la Torre, Vicente Aleixandre Benites Zapata

Abstract read
In one paragraph

Article in Revista peruana de medicina experimental y salud publica. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rodrigo Jesús Flores PalaciosHospital III Daniel Alcides Carrión, Tacna, Perú.ORCID http://orcid.org/0000-0001-5374-7915
Miguel Hueda ZavaletaHospital III Daniel Alcides Carrión, Tacna, Perú.ORCID http://orcid.org/0000-0002-8049-7787
Andrés Guillermo Gutiérrez AvilaHospital III Daniel Alcides Carrión, Tacna, Perú.ORCID http://orcid.org/0000-0002-4170-6603
Juan Carlos Gómez de la TorreLaboratorio Clínico Roe, Lima, Perú.ORCID http://orcid.org/0000-0003-4566-2027
Vicente Aleixandre Benites ZapataUniversidad San Ignacio de Loyola, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Lima, Perú.ORCID http://orcid.org/0000-0002-9158-1108

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe aimed to describe the main demographic, clinical, laboratory and therapeutic characteristics and to identify whether they are associated with mortality in tracheostomized patients. MATERIAL AND METHODS.: Retrospective cohort study in adult patients diagnosed with COVID-19, admitted to ICU (Intensive Care Unit) and requiring tracheostomy. Demographic, clinical, laboratory and treatment data were obtained from the medical records of patients admitted to Hospital III Daniel Alcides Carrión in Tacna. The Cox proportional hazards model was used for survival analysis and hazard ratios (HR) with their 95% confidence intervals (95%CI) were calculated. RESULTS.: We evaluated 73 patients, 72.6% were men, the most common comorbidities were obesity (68.5%), type 2 diabetes mellitus (35.6%), and arterial hypertension (34.2%). Thirty-seven percent of the participants died during their stay at the ICU. The median time from intubation to tracheostomy and the duration of tracheostomy was 17 (RIC: 15-21) and 21 (RIC: 3-39) days, respectively. Multivariate analysis showed that the factors associated with mortality were procalcitonin > 0.50 ng/dL at the time of tracheostomy (HRa: 2.40 95%CI: 1.03-5.59) and a PaO2/FiO2 ratio less than or equal to 150 mmHg (HRa: 4.44 95%CI: 1.56-12.60). CONCLUSIONS.: The factors associated with mortality at the time of tracheostomy were procalcitonin > 0.50 ng/dL and a PaO2/FiO2 ratio less than or equal to 150 mmHg.

Indexed as

COVID-19Diabetes Mellitus, Type 2Respiratory Distress SyndromeAdultFemaleHospital MortalityHospitalsHumansIntensive Care UnitsMalePeruProcalcitoninRetrospective StudiesProcalcitonin

Identifiers

PMID38597472
PMCPMC11138828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.